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Edited by Ned ManteiAbstract Hematopoietic progenitor kinase 1 (HPK1) is a
hematopoietic cell-restricted member of the Ste20 serine/threo-
nine kinase super family. We recently reported that HPK1 is in-
volved in c-Jun NH2-terminal kinase (JNK) signaling pathway
by sequential activation of MLK3–MKK7–JNK3 after cerebral
ischemia. Here, we used 4-amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo [3,4-d] pyrimidine (PP2) and MK801 to investigate
the events upstream of HPK1 in ischemic brain injury. Immuno-
precipitation and immunoblot results showed that PP2 and
MK801 signiﬁcantly decreased the activation of Src, HPK1,
MLK3, JNK3 and c-Jun, respectively, during ischemia/reperfu-
sion. Histology and TUNEL staining showed PP2 or MK801
protects against neuron death after brain ischemia. We speculate
that this unique signaling pathway through the tyrosine phos-
phorylation of HPK1 promotes ischemic brain injury by acti-
vated Src via N-methyl-D-aspartate receptor and, ultimately,
the activation of the MLK3–MKK7–JNK3 pathway after cere-
bral ischemia.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: HPK1; Cerebral ischemia; Src; N-methyl-D-
aspartate receptor (NMDAR); Neuroprotection; c-Jun NH2-
terminal kinase (JNK)1. Introduction
Hematopoietic progenitor kinase 1 (HPK1) is a member of
the germinal center kinase (GCK) sub-family of the Ste20
kinases [1]. The GCK/HPK1 family kinases are a group of
mammalian serine/threonine protein related to the yeast pro-bbreviations: GCK, germinal center kinase; HPK1, Hematopoietic
rogenitor kinase 1; JNK, c-Jun NH2-terminal kinase; MAPK
itogen-activated protein kinase; MKK7, MAPK kinase; NMDAR
-methyl-D-aspartate receptor; PCR, polymerase chain reaction
MSF, phenylmethylsulﬂuoride; PP2, 4-amino-5-(4-chlorophenyl)-7
t-butyl) pyrazolo [3,4-d] pyrimidine; PTK, protein-tyrosine kinase
DS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electropho
esis; SH2 and SH3, Src homology 2 and 3 domain, respectively; SLP
6, Src homology 2 domain-containing leukocyte phosphoprotein o
6 kDa; TCR, T cell receptor
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fhe Federtein kinase STE20. HPK1 is mainly expressed in hematopoietic
organs and cells [2]. HPK1 is involved in many cellular signal-
ing cascades including mitogen-activated protein kinase
(MAPK) signaling, antigen receptor signaling, apoptosis,
growth factor signaling, and cytokine signaling [1–3]. The
GCK/HPK1 family kinases act as mediators that link surface
receptors to the core c-Jun NH2-terminal kinase (JNK) signal-
ing cascades.
The role of HPK1 in biological processes is studied best in T
cells. HPK1, a 97-kDa serine/threonine kinase, contains a
STE20-like kinase domain in its N-terminus, four proline-rich
motifs, a caspase cleavage site, and a distal C-terminal Citron
homology domain. The studies in T cells reveal that HPK1 is
capable of interacting with a multitude of adaptor proteins
including members of the Grb2 family, Nck family, Crk fam-
ily, SLP-76 family, and actin-binding adaptors like HIP-55
[4–10]; the function of each adaptor protein is very diﬀerent
in terms of kinetics and signaling. HPK1 tyrosine phosphory-
lation and kinase activation depend on the presence of adaptor
proteins. In addition to T cell receptor (TCR) and B cell anti-
gen receptor engagement, ligand binding to transforming
growth factor-b receptor (TGF-bR) [11,12], the erythropoietin
receptor [13], Fas [14], and E prostanoid receptors [15] can also
induce HPK1 kinase activity. With the exception of TCR-med-
iated signal transduction in which some mechanisms control-
ling HPK1 activation have been delineated, the exact
biochemical mechanisms utilized by these receptors to activate
HPK1 remain poorly understood. Although HPK1 is selec-
tively expressed in hematopoietic tissues and cells, some breast
and prostate tumor cell lines also express HPK1. Therefore, it
is possible that HPK1 may play a role in other cells.
Our earlier studies showed that cerebral ischemia induced
robust HPK1 kinase activity through tyrosine phosphoryla-
tion. Knockdown of HPK1 expression provided neuroprotec-
tion by reducing activation of the MLK3–MKK7–JNK3
pathway following cerebral ischemia in the rat hippocampus
CA1 subﬁeld [25]. The studies above delineated the down-
stream cellular events of HPK1 signaling pathways in ischemic
brain injury. To gain more insight into the function of HPK1
in cerebral ischemia, we used PP2 (4-amino-5-(4-chloro-
phenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine), a selective
Src family kinase inhibitor, and MK801, a selective NMDA
receptor antagonist, before ischemia. Our results suggest a pre-
viously unknown mechanism of HPK1 activation in cerebral
ischemia: activated Src via N-methyl-D-aspartate receptor
(NMDAR) promotes HPK1 tyrosine phosphorylation and,ation of European Biochemical Societies.
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Fig. 1. PP2 inhibits the phosphorylation ofSrc, HPK1, MLK3, JNK3
and c-Jun in the hippocampal CA1 region after cerebral ischemia/
reperfusion. (A) Rats were pretreated with 15 lg of PP2 or PP3 in 10 ll
DMSO or the same dose of vehicle 30 min before ischemia followed by
6 h of reperfusion (R6h). Phosphorylation of Src, MLK3 and c-Jun
were examined by immunoblotting (IB) analysis with the anti-p-Src,
anti-p-MLK3 and anti-p-c-Jun antibody, phosphorylation of HPK1
and JNK3 were examined by immunoprecipitation (IP) with anti-p-
Tyr and anti-p-JNKs followed by IB with antibody against HPK1 and
JNK3. (B) The protein levels of total Src, HPK1, MLK3, JNK3 and c-
Jun were examined by IB analysis with anti-Src, anti-HPK1, anti-
MLK3, anti-JNK3 or anti-c-Jun antibody. (C) Corresponding bands
were scanned and the optical density (OD) was represented as folds
versus sham control. Data were the means ± S.D. and were expressed
as folds versus sham. aP < 0.05 versus sham; bP < 0.05 versus
respective reperfusion groups (n = 3).2. Materials and methods
2.1. Animals and treatments
Adult male SD rats (Shanghai Experimental Animal Center, Chinese
Academy of Science) weighing 200–250 g were provided with water
and food ad libitum. The experimental procedures were approved by
the local legislation for ethics when carrying out experiments on ani-
mals. Rats were given MK801 (3 mg/kg dissolved in saline) [16] or
vehicle (saline) by intraperitoneally (i.p.) injection 60 min prior to
ischemia. Fifteen micrograms of PP2 or PP3 [17] dissolved in 10 ll di-
methyl sulfoxide (DMSO) was given 30 min before ischemia by means
of intracerebroventricular infusion. An equal volume of DMSO infu-
sion in the rats served as vehicle control. Drug infusion was performed
using a microinjector through both cerebral ventricles (from the breg-
ma: anteroposterior, 0.8 mm; lateral, 1.5 mm; depth, 3.5 mm) at a rate
of 1 ll/min. Transient brain ischemia was induced by four-vessel occlu-
sion (4-VO) as described before [18]. Brieﬂy, under anesthesia with
chloral hydrate (300 mg/kg, i.p.), both vertebral arteries were occluded
permanently by electrocautery. On the following day, both carotid
arteries were occluded with aneurysm clips to induce cerebral ischemia.
After 15 min of the occlusion, the aneurysm clips were removed for
reperfusion. Sham controls were performed using the same surgical
procedures except that the carotid arteries were not occluded.
2.2. Sample preparation
For brain tissue preparation, rats were killed under anesthesia at 6 h,
3 days and 5 days of reperfusion after 15 min of global cerebral ische-
mia. Whole brains were removed for dissections and the hippocampal
CA1 regions were microdissected from both sides of the hippocampal
ﬁssure and immediately frozen in liquid nitrogen. Tissues were homog-
enized in ice-cold homogenization medium consisting of 50 mM
HEPES (pH 7.4), 150 mM NaCl, 12 mM b-glycerophosphate, 3 mM
dithiothreitol (DTT), 2 mM sodium orthovanadate (Na3VO4) (Sigma,
St. Louis, MO, USA), 1 mM EGTA, 1 mM NaF, 1 mM phenylmeth-
ylsulfonyl ﬂuoride (PMSF), 1% Triton X-100, and inhibitors of prote-
ase and enzymes. The homogenates were centrifuged at 15000 · g for
20 min at 4 C, supernatants were collected, and stored at 80 C for
use. The protein concentrations were determined by the method of
Lowry with bovine serum albumin (BSA) as standard.
2.3. Antibodies and reagents
The following primary antibodies were used: goat polyclonal anti-
HPK1 (sc-6231), rabbit polyclonal anti-MLK3 (sc-13072), anti-p-
JNKs (sc-6254), anti-c-Jun (sc-1694), and mouse monoclonal anti-p-
c-Jun (sc-822) were purchased from Santa Cruz Biotechnology. Anti-
phospho-Src (pY416) (SA-314) was purchased from Biomol Biotech-
nology Inc. Anti-Src(05-184), rabbit polyclonal anti-JNK3 antibody
(06-749), monoclonal antiphosphotyrosine Ab(4G10) were obtained
from Upstate Biotechnology Inc. Rabbit polyclonal anti-p-MLK3
was obtained from Cell Signal Biotechnology. The secondary antibod-
ies used in our experiment were goat anti-mouse IgG, goat anti-rabbit
IgG and donkey anti-goat IgG. They were from Sigma. PP2(529573)
and PP3(529574) were purchased from Calbiochem Biotechnology.
MK-801 was purchased from Sigma. All the other chemicals were from
Sigma unless indicated otherwise.
2.4. Immunoprecipitation
Tissue homogenates (400 lg of protein) were diluted fourfold with
50 mM HEPES buﬀer (pH 7.4), containing 10% glycerol, 150 mM
NaCl, 1% Triton X-100, 0.5% NP-40, and 1 mM each of EDTA,
EGTA, PMSF, and Na3VO4. Samples were preincubated for 1 h with
20 ll protein A Sepharose CL-4B (Amersham, Uppsala, Sweden) at
4 C, and then centrifuged to remove proteins that adhered non-
speciﬁcally to protein A-Sepharose. The supernatants were incubated
with 1–2 lg primary antibodies for 4 h at 4 C. Protein A was added
to the tube for another 2 h incubation. Samples were centrifuged
at 10000 · g for 2 min at 4 C and the pellets were washed with immu-
noprecipitation (IP) buﬀer for three times. Bead-bound proteins were
eluted by boiling at 100 C for 5 min in sodium dodecylsulfate–polyacrylamide gel electrophoresis loading buﬀer and then isolated
by centrifuging. The supernatants were used for immunoblot
analysis.
2.5. Immunoblot
For immunoblot (IB), proteins were separated on 10% polyacryl-
amide gels and then electrotransferred onto a nitrocellulose membrane
(Amersham, Buckinghamshire, UK). After being blocked for 3 h in
Tris-buﬀered saline with 0.1% Tween-20 (TBST) and 3% bovine serum
albumin (BSA), membranes were incubated overnight at 4 C with pri-
mary antibodies in TBST containing 3% BSA. Membranes were then
washed and incubated with alkaline phosphatase-conjugated second-
ary antibodies in TBST for 2 h and developed using NBT/BCIP color
substrate (Promega, Madison, USA). The densities of the bands on the
membrane were scanned and analyzed with an image analyzer (Lab-
Works Software, UVP Upland, CA, USA).
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Rats were anesthetized with chloral hydrate and underwent trans-
cardial perfusion with 0.9% saline followed by 4% paraformaldehyde
in 0.1 M PBS. Brains were removed, post-ﬁxed overnight in parafor-
maldehyde, processed and embedded in paraﬃn. Coronal brain sec-
tions (6 lm-thick) were cut on a microtome (Leica RM2155,
Nussloch, Germany). Sections were deparaﬃnized in xylene and
rehydrated in a gradient of ethanol and distilled water. High-temper-
ature antigen retrieval was performed in 1 mM citrate buﬀer. To
block endogenous peroxidase activity, sections were incubated for
2 h in a solution containing 0.01% sodium azide and 0.1% H2O2 in
PBS. After being blocked with 5% (v/v) normal goat serum in
0.01 M PBS (pH 7.4) for 1 h at 37 C, the sections were then incu-
bated in the primary antibodies overnight at 4 C. Alternate sections
from each brain were incubated without primary antibody as nega-
tive controls. After washing three times in PBS, the sections were
incubated for 2 h in biotinylated goat anti-rabbit secondary antibody
(1:200 dilution; Vector Laboratories, Burlingame, CA, USA) made
up in 0.1% BSA, 0.3% Triton X-100 and 1% normal goat serum in
PBS. Sections were washed and incubated with avidin-conjugated
horseradish peroxidase (diluted 1:200 in 0.3% Triton X-100) for 1 h
at 37 C, followed by avidin–biotin–peroxidase (ABC, Vector Labo-
ratories) at room temperature. The sections were examined by light
microscopy.M
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For histology, the rats subjected to 5 days of reperfusion were per-
fusion-ﬁxed with 4% paraformaldedhyde in 0.1 M phosphate buﬀer
(pH 7.4) under anesthesia. The paraﬃn embedded brain sections
(5 lm) were prepared and stained with hematoxylin and eosine.
2.8. TUNEL staining
TUNEL staining was performed using an ApopTag Peroxidase In
Situ Apoptosis Detection Kit according to the manufacturers protocol
with minor modiﬁcations. The paraﬃn-embedded coronal sections
were deparaﬃnized and rehydrated, and then treated with protease
K at 20 mg/ml for 15 min at room temperature. Sections were incu-
bated with reaction buﬀer containing TdT enzyme and at 37 C for
1 h. After washing with stop/wash buﬀer, sections were treated with
anti-digoxigenin conjugate for 30 min at room temperature and subse-
quently developed colour in peroxidase substrate. The nuclei were
lightly counterstained with 0.5% methyl green.
2.9. Statistical evaluation
Values were expressed as mean S.D. and obtained from at least three
separate rats. Statistical analysis of the results was carried out by one-
way analysis of the variance (ANOVA) followed by the Duncans new
multiple range method or Newman–Keuls test. Diﬀerences of P < 0.05
were considered signiﬁcant.K801
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3.1. Src is involved in the HPK1–MLK3–JNK3 signaling
pathways
Our earlier reports indicated that ischemia/reperfusion in-
duced the activation of SrcPTKs and NMDAR after 15 min
ischemia followed by 6 h of reperfusion [19,20]. So ﬁrstly, in or-
der to investigate whether Src was involved in HPK1 signaling
pathway after cerebral ischemia, PP2 (15 lg dissolved in 10 ll
DMSO), a selective Src family kinase inhibitor, was applied
30 min before ischemia by intracerebroventricular (i.c.v.) injec-
tion. PP3 (4-amino-7-phenylpyrazolo [3,4-d] pyrimidine), a
non-active analogue of PP2, was used as a negative control.
Vehicle controls received equal volume of DMSO. As shown
in Fig. 1, the phosphorylation of Src, HPK1, MLK3, JNK3
and c-Jun increased markedly after 15 min ischemia followed
by 6 h of reperfusion. PP2, but not vehicle (DMSO) or PP3, lar-
gely blocked this increase. Moreover, coapplication PP2 and
HPK1 antisense oligodeoxynucleotides (AS) had signiﬁcant
strong eﬀect compared with sole application of PP2 or HPK1
AS (supplementary ﬁgure). The results of immunohistochemis-
try also revealed that weak p-Src (Fig. 2Aa, h) and p-c-Jun (Fig.
2Ba, h) immunoreactivity was detected in the cytosol of hippo-
campal CA1 in the sham group. On the contrary, p-Src (Fig.
2Ab, i) and p-c-Jun (Fig. 2Bb, i) immunoreactivity was signiﬁ-
cantly increased after 6 h reperfusion compared with the sham
group. Immunoreactivity for p-Src (Fig. 2Af, m) and p-c-Jun
(Fig. 2Bf, m) after ischemia 6 h reperfusion was signiﬁcantly
inhibited by application of PP2. Vehicle control (DMSO) or
negative control (PP3) had no eﬀect on p-Src (Fig. 2Ac, j and
Ae, l) or p-c-Jun (Fig. 2Bc, j, and Be, l). These results indicate
that Src is involved in the HPK1–MLK3–JNK3 signaling path-
ways after transient cerebral ischemia.O
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Fig. 3. MK801 inhibits the phosphorylation of Src, HPK1, MLK3,
JNK3 and c-Jun in hippocampal CA1 region after cerebral ischemia/
reperfusion. (A) Rats were given MK801 (3 mg/kg dissolved in saline)
or the same dose of vehicle by i.p. administration 60 min prior to3.2. NMDA receptor is involved in the activation of HPK1
during ischemia/reperfusion
Furthermore to address which cell surface receptor is linked
to HPK1 activation in ischemic brain injury, we injected (i.p.)
MK801, a selective NMDA receptor antagonist, 60 min prior
to ischemia. Six hours post-ischemia we analyzed the protein
levels of p-Src, p-HPK1, p-MLK3, p-JNK3, and p-c-Jun.
Immunoblot (Fig. 3) showed that the increased phosphoryla-
tion of Src, HPK1, MLK3, JNK3 and c-Jun induced by ische-
mia/reperfusion were signiﬁcantly suppressed by MK801.
Immunohistochemistry revealed weak p-Src (Fig. 2Aa, h)
and p-c-Jun (Fig. 2Ba, h) immunoreactivity in the cytosol of
hippocampal CA1 in the sham group. On the contrary, p-Src
(Fig. 2Ab, i) and p-c-Jun (Fig. 2Bb, i) immunoreactivity was
signiﬁcantly increased after 6 h reperfusion compared with
the sham group. No inhibitory eﬀects of vehicle control (saline)
on p-Src (Fig. 2Ad, k) or p-c-Jun (Fig. 2Bd, k) immunoreactiv-
ity were detected. However, p-Src (Fig. 2Ag, n) and p-c-Jun
(Fig. 2Bg, n) immunoreactivity after ischemia 6 h reperfusion
was signiﬁcantly inhibited by application of MK801. These
data suggest that NMDA receptor is involved in the activation
of HPK1 by tyrosine phosphorylation after cerebral ischemia.
ischemia. Homogenate samples were from hippocampal CA1 region of
sham control, or 15 min of ischemia followed by 6 h of reperfusion, or
vehicle, or drug administration of MK801 groups. Phosphorylated and
total protein levels were determined as described in the legend to Fig.
1. Data were the mean ± S.D. and were expressed as folds versus sham.
aP < 0.05 versus respective sham; bP < 0.05 versus respective reperfu-
sion groups (n = 3).3.3. PP2 or MK801 is neuroprotective after cerebral ischemia in
rat hippocampal CA1 subﬁeld
The hippocampal CA1 subﬁeld is the brain region most vul-
nerable to ischemia. To investigate the protective eﬀect of PP2and MK801, histology analysis was performed to examine the
survival of hippocampal CA1 pyramidal neurons in rats sub-
jected to 5 days of reperfusion following ischemia (I/R5d),
which induced delayed neuronal death. Under a light micro-
scope, the live CA1 pyramidal neurons showed round cell
bodies and plain stained nuclei (Fig. 4Aa, h). After 5 days of
reperfusion following brain ischemia, most of the hippocampal
CA1 pyramidal neurons were shrunken with pyknotic nuclei
and counted as dead cells(Fig. 4Ab, i). Pretreatment with
PP2 or MK801 before ischemia markedly increased the num-
ber of surviving neurons (Fig. 4Af, m, g, n and B). Infusion
of DMSO or saline or PP3 had no eﬀect on the post-ischemic
cell death (Fig. 4Ac, j, d, k, e, l and B). Statistical analysis of
neuronal density for each group is shown in Fig. 4B.
TUNEL staining was performed to further explore the role
of PP2 and MK801 in ischemia-induced apoptosis. Rats were
pretreated with PP2 or MK801 before ischemia. After 3 days
reperfusion, rats were perfusion-ﬁxed with paraformaldehyde
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Fig. 4. Neuroprotection of PP2 and MK801 against cerebral ischemia/ reperfusion-induced apoptotic neuronal death in hippocampal CA1 neurons
(A) Cresyl Violet staining was performed to examine the survival of neurons in the pyramidal cell layer of the hippocampal CA1 subﬁeld
Representative photomicrographs of Cresyl Violet-stained sections from the hippocampus in sham group (a, h), and 15 min of ischemia followed by 5
days of reperfusion (R5d) (b, i), administration of DMSO (c, j), PP3 (e, l), PP2 (f, m) 30 min before ischemia, saline (d, k), MK801(g, n) 60 min before
ischemia. Treatment with PP2 and MK801signiﬁcantly increased the number of the surviving neurons at 5 days of reperfusion in the CA1 region. (B
Data were obtained from six independent animals and a typical set of results is presented. Cell density was expressed as the number of cells per 1 mm
length of the CA1 pyramidal cells counted under a light microscope. Data are the means ± S.D. aP < 0.05 versus sham; bP < 0.05 versus I/R 5 days
groups (n = 6). a–g: ·40; f–n; ·400. Scale bars in g = 200 lm; bar in n = 20 lm. (C) Representative hippocampal photo micrographs of TUNEL
staining. Rats were subjected to sham operation (a, h) or 15 min of ischemia followed by 3 days of reperfusion (R3d) (b, i), administration of DMSO
(c, j), saline (d, k), PP3 (e, l), PP2(f, m) and MK801 (g, n). Data were obtained from six independent animals. a–g: ·40; f–n; ·400. Scale bars in
g = 200 lm; bar in n = 20 lm.
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CA1 pyramidal cells in hippocampus. As shown in Fig. 4C,
a signiﬁcant number of TUNEL-positive cells were observed
3 days after ischaemia (Fig. 4Cb, i). Pretreatment with PP2
or MK801 signiﬁcantly decreased TUNEL-positive cells (Fig.
4Cf, m and Cg, h). However, as a control, DMSO, saline
and PP3 did not show any protection (Fig. 4Cc, j, d, k, e
and l).
The above results suggest that PP2 or MK801 protects
against the hippocampal CA1 pyramidal cell death after tran-
sient global brain ischemia.4. Discussion
HPK1 has been proved to play a critical role in the regula-
tion of the JNK pathway in lymphocytes [1]. Our earlier results
suggested that HPK1 is involved in the JNK signaling pathway
by sequential activation of MLK3–MKK7–JNK3, which was
induced by cerebral ischemia. These ﬁndings prompted us to
investigate the underlying pathways upstream of HPK1. Our
earlier work indicated that Src PTKs are involved in post-
ischemic neuronal cell death [19,20]. To elucidate whether
Src aﬀects the activation of HPK1 after cerebral ischemia,
we used PP2 to inhibit Src PTKs 30 min before ischemia. We
found that the increased tyrosine phosphorylation of HPK1
and p-MLK3 were strongly reduced at 6 h reperfusion after
15 min of ischemia. These results indicate that Src is involved
in the activation of HPK1 induced by brain ischemia. HPK1 or
MAP4K1 is a hematopoietic-speciﬁc mammalian STE20-like
protein serine/threonine kinase, which was cloned from mouse
hematopoietic progenitor cells using a polymerase chain reac-
tion (PCR) based subtraction strategy [1,2]. HPK1 comprises
four proline-rich motif (-P-x-x-P) in the middle. These pro-
line-rich motifs are capable of binding proteins that contain
SH3 domains [6,8]. The Src chain includes SH3 domain and
SH2 domain. Src looks for polyproline helices with its SH3
domain and meanwhile it looks for phosphorylated tyrosine
residues with its SH2 domain [21]. HPK1 tyrosine phosphory-
lation and kinase activation depend on the presence of adaptor
proteins. Thus, we infer that activated Src may be associated
with the proline-rich motif of HPK1 through its SH3 domain
to regulate the downstream signaling events.
Adaptor proteins are required not only for downstream gene
transcription, but also for linking HPK1 to cell surface recep-
tors. The evidence above prompted us to further investigate
which cell surface receptor was involved in the induction of
Src activation. Cumulative evidence reveal that Src-family
PTKs act as a molecular scaﬀold to anchor these PTKs to
NMDAR [22,23]. Excessive release of glutamate causes over-
activation of glutamate receptors, mainly NMDA receptors,
and subsequently calcium overloading, which is known as
excitotoxicity, and then activates calcium-dependent signaling
cascade reactions of postsynaptic neurons that eventually lead
to neuronal death [24]. In this study, we used MK801, a selec-
tive NMDA receptor antagonist, to assess whether NMDAR
is the cell surface receptor in HPK1 signaling pathway induced
by ischemia. The results of both immunoprecipitation and
immunohistochemistry showed that activated Src via
NMDAR promoted HPK1 tyrosine phosphorylation which
aggravated ischemic brain injury. And this injury was signiﬁ-
cantly attenuated in MK801-administrated rats comparing tosaline-treated groups. These data suggest that the activation
of HPK1 is induced by NMDAR after cerebral ischemia.
In summary, we have identiﬁed a previously unknown regu-
latory function of HPK1 in ischemic brain injury. Activated
Src via NMDAR promotes HPK1 tyrosine phosphorylation
and, ultimately, results in the brain injury by the activation
of MLK3–MKK7–JNK3 pathway after cerebral ischemia.
Here we delineate the possible molecular mechanisms of the
protection by PP2 and MK801 against ischemic cell damage
in rat global brain ischemia model. Such a possibility, if veri-
ﬁed, might lead to the development of a novel therapeutic ap-
proach for ischemic brain injury.
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